Carisma reports preliminary Phase 1 data for CT-0508; 40.7% target lesion reduction in monotherapy

Carisma Therapeutics Inc.

In 14 monotherapy patients, 40.7% of target lesions reduced in size on ≥1 scan across all anatomic sites.
Combination sub-study of CT-0508 with pembrolizumab enrolled 6 patients; data from first 3 shown.
First two combination patients received corticosteroids prior to pembro; both had progressive disease as best response.
Third combination patient achieved stable disease with 46% reduction in one target lesion; PD due to new brain met.
Company notes corticosteroids may reverse CT-0508 activity based on in vitro cell death data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.